X

Trial Profile

A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL in Treatment-naïve Subjects With Fabry Disease

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 19 Jun 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Agalsidase alfa (Primary)
Indications Fabry's disease
Focus Therapeutic Use
Sponsors Shire

Most Recent Events

09 Feb 2023 This trial has been discontinued in Poland, according to European Clinical Trials Database record
06 Jan 2023 This trial has been discontinued in Greece, according to European Clinical Trials Database record
31 Dec 2022 This trial has been discontinued in Finland according to European Clinical Trials Database record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com